## Background: Health-related quality of life (qol) provides a measure of the patient's perception of his life after treatment. this study was undertaken to assess changes in qol and swallowing in patients undergoing concurrent chemoradiotherapy (cr) for head and neck cancer. the assessment tools c
Swallowing and speech ability after treatment for head and neck cancer with targeted intraarterial versus intravenous chemoradiation
β Scribed by Lisa A. Newman; K. Thomas Robbins; Jeri A. Logemann; Alfred W. Rademaker; Cathy L. Lazarus; Annette Hamner; Stephanie Tusant; Cheng Fang Huang
- Book ID
- 102232414
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 98 KB
- Volume
- 24
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Objective
RADPLAT (concurrent selective supradose intraarterial cisplatin and externalβbeam irradiation) delivers extraordinarily high cisplatin concentration to head and neck structures. This study was designed to quantify and compare RADPLAT and systemic chemoradiation treatment effects on swallowing and speech.
Methods
Videofluorographic swallowing studies and articulation testing of 14 head and neck cancer patients treated with RADPLAT were compared with 16 treated with systemic chemoradiation 1 month after treatment.
Results
RADPLAT and systemic chemoradiation patients did not differ significantly on most swallow outcome measures, and there was significantly less aspiration on 1 and 3 mL liquid for RADPLAT individuals. Speech function was comparable except for RADPLAT's significantly worse /s, z/ productions.
Conclusions
Increased concentration of cisplatin to the head and neck did not result in generally reduced swallowing or articulatory function. Β© 2002 John Wiley & Sons, Inc. Head Neck 24: 68β77, 2002.
π SIMILAR VOLUMES
## Abstract ## Background. Head and neck cancer patients treated with chemoradiation have difficulty eating a normal diet. This study was designed to characterize eating ability over 12 months after chemoradiation treatment. Analyses take patient dropout into account. ## Methods: Two hundred fif